A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Detalles Bibliográficos
Autores principales: Kim, Miso, Lee, Jeong-Ok, Koh, Jiwon, Kim, Tae Min, Lee, Ji Yun, Jeon, Yoon Kyung, Keam, Bhumsuk, Kim, Dong-Wan, Lee, Jong Seok, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327727/
https://www.ncbi.nlm.nih.gov/pubmed/33792222
http://dx.doi.org/10.3324/haematol.2021.278301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327727/
https://www.ncbi.nlm.nih.gov/pubmed/33792222
http://dx.doi.org/10.3324/haematol.2021.278301

Ejemplares similares